Clinical Trials on Adenocarcinoma Breast

Total 23181 results

Pfizer

Active, not recruiting

Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)

Breast Neoplasms | Colorectal Cancer | Metastatic HER2+ Advanced Breast Cancer | Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)

China
Stanford University

Active, not recruiting

Accelerated Partial Breast Irradiation Following Lumpectomy for Breast Cancer

Breast Cancer | Carcinoma, Ductal

United States
Columbia University

Withdrawn

Sentinel Lymph Node Identification in the Axilla of Women With Breast Cancer Using Ultrasound and Iron Injection

Breast Neoplasm | Carcinoma, Intraductal, Noninfiltrating | Carcinoma, Ductal, Breast
German Breast Group
Celgene Corporation; Amgen

Completed

Denosumab as an add-on Neoadjuvant Treatment (GeparX) (GeparX)

Inflammatory Breast Cancer | HER2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage III

Germany
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); Puma Biotechnology, Inc.

Recruiting

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Invasive Breast Lobular Carcinoma | Anatomic Stage I Breast Cancer | Anatomic Stage II Breast Cancer | Anatomic Stage III Breast Cancer

United States
University of Chicago
National Cancer Institute (NCI)

Withdrawn

Magnetic Resonance Thermal Image Guided Laser Interstitial Thermal Therapy in Treating Patients With Breast Cancer

Stage IA Breast Cancer | Stage IB Breast Cancer | Ductal Breast Carcinoma in Situ | Invasive Ductal Breast Carcinoma

United States
Northwestern University
National Cancer Institute (NCI)

Completed

4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ

Estrogen Receptor-positive Breast Cancer | Ductal Breast Carcinoma in Situ

United States
European Institute of Oncology

Active, not recruiting

CDH1 Germline Mutations in Lobular Breast Cancer

Lobular Breast Carcinoma | CDH1 Gene Inactivation

Italy
Medical University of South Carolina

Terminated

Vitamin D3 (Vit D3) Supplementation and T Cell Immunomodulation in Patients With Newly Diagnosed Operative Invasive Ductal Breast Carcinoma

Newly Diagnosed Operative Invasive Ductal Breast Carcinoma Stage I-II

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH)

Active, not recruiting

Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Invasive Breast Lobular Carcinoma | Metastatic Breast Lobular Carcinoma

United States
Northwestern University
National Cancer Institute (NCI); Pfizer; University of California, San Francisco and other collaborators

Recruiting

The PROMISE Study: Duavee in Women With DCIS

Postmenopausal | Ductal Breast Carcinoma In Situ

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group

Active, not recruiting

MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ

Ductal Breast Carcinoma In Situ

United States
St. Joseph Hospital of Orange

Completed

Single Fraction Intraoperative Radiotherapy

Stage 0 Breast Carcinoma | Stage I Breast Carcinoma | Stage II Breast Carcinoma | Invasive Ductal and Invasive Lobular Breast Carcinoma

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Invasive Ductal Breast Carcinoma

United States
Virginia Commonwealth University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Active, not recruiting

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IIA Breast Cancer | Stage IIB Breast Cancer | HER2/Neu Negative | Progesterone Receptor Negative | Estrogen Receptor-positive Breast Cancer | Breast Adenocarcinoma | Progesterone Receptor Positive... and other conditions

United States
Effector Therapeutics

Terminated

A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC

Hepatocellular Carcinoma | Triple Negative Breast Cancer

United States
West German Study Group
GlaxoSmithKline

Terminated

Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer

Carcinoma, Ductal, Breast

Germany
Seagen Inc.
RemeGen Co., Ltd.

Recruiting

A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors

Stomach Neoplasms | Breast Neoplasms | Triple Negative Breast Neoplasms | Gastroesophageal Junction Adenocarcinoma | HER2 Positive Breast Neoplasms | HER2 Low Breast Neoplasms

United States, Canada
Groupe Hospitalier Paris Saint Joseph

Withdrawn

Retrospective Analysis of the Expression of the Neurotensin Receptor by Metastatic Lung Adenocarcinomas (NTS)

Metastatic Lung Adenocarcinomas
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Completed

Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer

Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Invasive Lobular Breast Carcinoma | Invasive Ductal Breast Carcinoma | Mucinous Ductal Breast Carcinoma | Papillary Ductal Breast Carcinoma | Tubular Ductal Breast Carcinoma

United States
University of Miami

Active, not recruiting

Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction

Breast Cancer | Ductal Carcinoma

United States
National Cancer Institute (NCI)

Completed

Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer

Healthy, no Evidence of Disease | Lobular Breast Carcinoma in Situ

United States
Stanford University

Recruiting

Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma (NORDIS)

Ductal Breast Carcinoma in Situ

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer

Breast Carcinoma | Recurrent Breast Carcinoma | Breast Ductal Carcinoma In Situ | Invasive Breast Carcinoma

United States
GC Cell Corporation

Not yet recruiting

Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

Breast Cancer | Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Australia
Artiva Biotherapeutics, Inc.

Not yet recruiting

A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors

Breast Cancer | Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, United States
Memorial Sloan Kettering Cancer Center

Recruiting

Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer

Breast Cancer | DCIS | Invasive Ductal Carcinoma, Breast | Invasive Ductal Breast Carcinoma | DCIS Grade 1 | DCIS Grade 2

United States
National Cancer Institute (NCI)

Completed

Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

Breast Ductal Carcinoma In Situ

United States
National Cancer Institute (NCI)

Active, not recruiting

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Breast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | Multicentric Breast Carcinoma | Multifocal Breast Carcinoma | Synchronous Bilateral Breast Carcinoma

United States, France, Spain, Canada, Saudi Arabia, Puerto Rico, Korea, Republic of, Ireland, Colombia, Mexico
University of Southern California
National Cancer Institute (NCI)

Completed

Extent of Breast Cancer and the Role of Pre-Operative Sonography and MRI

Stage II Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Ductal Breast Carcinoma In Situ

United States
National Cancer Institute (NCI)

Completed

Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ

HER2/Neu Positive | Ductal Breast Carcinoma In Situ

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Effects of Chemotherapy on Intestinal Bacteria in Patients With Newly Diagnosed Breast Cancer

Stage I Breast Cancer | Stage IIIA Breast Cancer | Invasive Breast Carcinoma | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Ductal Breast Carcinoma In Situ

United States
Sohag University

Not yet recruiting

EpCAM and p53 Expressions in Infiltrating Duct Carcinoma of the Breast

Invasive Breast Cancer
Università Vita-Salute San Raffaele
IRCCS San Raffaele; Associazione Italiana per la Ricerca sul Cancro

Not yet recruiting

18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer (FESTA)

Breast Cancer Female | Lobular Breast Carcinoma | Luminal A Breast Cancer | PET/MRI | Axillary Lymphadenopathy
German Breast Group
Roche Pharma AG; Celgene Corporation

Completed

Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) (GeparSepto)

Inflammatory Breast Cancer | HER-2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage III | Inflammatory Breast Cancer Stage IV

Germany
German Breast Group
GlaxoSmithKline; Roche Pharma AG; Teva Pharmaceuticals USA

Completed

Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer (GeparSixto)

Inflammatory Breast Cancer | HER-2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage III | Inflammatory Breast Cancer Stage IV

Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Endometrial Adenocarcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast... and other conditions

United States
Coordinación de Investigación en Salud, Mexico

Recruiting

Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer.

Stage 0 Breast Cancer | Stage I Breast Cancer | Invasive Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Ductal Breast Carcinoma in Situ | Early-stage Breast Cancer

Mexico
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Invasive Lobular Breast Carcinoma | Invasive Ductal Breast Carcinoma

United States, Puerto Rico
Roswell Park Cancer Institute

Recruiting

A Patient Navigation Program for Addressing Disparities in Breast Cancer Care

Breast Carcinoma | Breast Ductal Carcinoma in Situ

United States
University of Utah

Active, not recruiting

Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer (NOVEMBER)

Stage 0 Breast Cancer | Stage I Breast Cancer | Stage II Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Ductal Breast Carcinoma In Situ

United States
Northwestern University
National Cancer Institute (NCI); BHR Pharma, LLC

Recruiting

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

Estrogen Receptor Positive | Ductal Breast Carcinoma In Situ

United States
University of California, San Francisco
Puma Biotechnology, Inc.

Completed

Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib

HER2-positive Breast Cancer | Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States
City of Hope Medical Center

Completed

Bilingual Breast Cancer Educational Intervention for Hispanic Women With Stage I, Stage II, or Stage III Breast Cancer and Their Families or Caregivers

Breast Cancer | Stage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Ductal Breast Carcinoma in Situ

United States
AstraZeneca

Completed

Study of Tremelimumab in Patients With Advanced Solid Tumors

Pancreatic Ductal Adenocarcinoma | Triple-negative Breast Cancer | Urothelial Bladder Cancer

United States, Belgium, Korea, Republic of, Poland, Netherlands
First Hospital of China Medical University
Jilin Provincial Tumor Hospital; The First Hospital of Jilin University; Second... and other collaborators

Unknown

Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast

Breast Cancer

China
University of Southern California
AstraZeneca

Terminated

A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)

Breast Carcinoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ

Breast Cancer | Invasive Breast Cancer | Lobular Carcinoma

United States
Ikena Oncology
Gilead Sciences

Terminated

A Study of PY314 in Subjects With Advanced Solid Tumors

Renal Cell Carcinoma | Breast Cancer | Gynecologic Cancer | Colorectal Cancer | Ovarian Cancer | Lung Adenocarcinoma | Triple Negative Breast Cancer | Advanced Solid Tumor | Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer

United States
Auxilio Mutuo Cancer Center

Unknown

"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" (NACprotocol)

Infiltrating Duct and Lobular Carcinoma In Situ | Invasive Lobular Breast Carcinoma | Inflammatory Breast Carcinoma

Puerto Rico

Clinical Trials on Adenocarcinoma Breast

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations